Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID IV.
PANTOPRAZOLE SODIUM vs PREVACID IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of gastric parietal cells. This action is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
30 mg intravenous infusion over 30 minutes once daily for up to 7 days; may switch to oral therapy when patient can tolerate oral intake.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Terminal elimination half-life is approximately 1.5–2 hours in healthy individuals; however, the pharmacodynamic half-life (duration of acid suppression) is longer (up to 24 hours) due to accumulation in parietal cell canaliculi.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 75% excreted in urine as metabolites, with less than 1% as unchanged drug; about 20% eliminated in feces via bile.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor